Qi Biodesign
Latest round
- Series A
Last raised
- May 2026
Total raised
- $58M
Investors
- 12
About Qi Biodesign
, trading as Qi Biodesign, operates as a biotechnology company that focuses on the R&D of gene editing technology for plant breeding. The company was established by Doctor Kevin Zhao and gene editing scientist Caixia Gao. It acquired 2 Chinese Plant Gene Editing Safety Certificates and the US USDA Exempt Gene Editing Product Certification. Qi Biodesign's main business is the research and development and application of gene editing technology. Develop new gene editing technologies to create excellent biological traits and products. The company has built the SEEDIT™ biotechnology and trait engineering platform. The platform can achieve multiple gene or genome operations such as precise gene knockout, base substitution, fine regulation of gene expression, and precise insertion of large DNA fragments. The company has established an independent and efficient delivery system for more than 40 crops. The company generates revenue by providing gene editing technologies and related services.
Who invested in Qi Biodesign
12 investors across 3 rounds
See all investors in Qi Biodesign
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Qi Biodesign
Who invested in Qi Biodesign?
Qi Biodesign has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Qi Biodesign raised?
Qi Biodesign has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Qi Biodesign last raise money?
Qi Biodesign's most recent round on record is a Series A, in May 2026.
What does Qi Biodesign do?
, trading as Qi Biodesign, operates as a biotechnology company that focuses on the R&D of gene editing technology for plant breeding.
Where is Qi Biodesign headquartered?
Qi Biodesign is headquartered in Suzhou, China.
Which VCs invest in companies like Qi Biodesign?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Qi Biodesign's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Qi Biodesign? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.